• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The in-vitro activity of piperacillin/tazobactam, ciprofloxacin, ceftazidime and imipenem against multiple resistant gram-negative bacteria.

作者信息

Mehtar S, Drabu Y J, Blakemore P H

机构信息

Department of Microbiology, North Middlesex Hospital, Edmonton, London, UK.

出版信息

J Antimicrob Chemother. 1990 Jun;25(6):915-9. doi: 10.1093/jac/25.6.915.

DOI:10.1093/jac/25.6.915
PMID:2164513
Abstract

One hundred and fifty Gram-negative bacterial strains including respiratory pathogens, such as Haemophilus influenzae and Branhamella catarrhalis, and Enterobacteriaceae with known resistance to beta-lactam and other antibiotics were tested in vitro for sensitivity to piperacillin, piperacillin/tazobactam (ratio 8:1), ceftazidime, ciprofloxacin and imipenem. A 16-fold or greater reduction in the MIC90 of piperacillin was achieved by the addition of tazobactam, in the respiratory pathogens, thus bringing them within the susceptible range. Among the Enterobacteriaceae, a 32-fold or greater reduction in the MIC90 was found for Providencia stuartii, Proteus mirabilis and Aeromonas hydrophila. When compared with the other three antimicrobials, the combination was found to be active against fewer species of multiply resistant Enterobacteriaceae, but equally effective against H. influenzae and B. catarrhalis.

摘要

相似文献

1
The in-vitro activity of piperacillin/tazobactam, ciprofloxacin, ceftazidime and imipenem against multiple resistant gram-negative bacteria.
J Antimicrob Chemother. 1990 Jun;25(6):915-9. doi: 10.1093/jac/25.6.915.
2
Comparative in vitro activity of piperacillin/tazobactam against gram-negative bacilli.哌拉西林/他唑巴坦对革兰氏阴性杆菌的体外比较活性
S Afr Med J. 1996 Oct;86(10):1276-80.
3
Multicenter evaluation of the in vitro activity of piperacillin-tazobactam compared with eleven selected beta-lactam antibiotics and ciprofloxacin against more than 42,000 aerobic gram-positive and gram-negative bacteria. In Vitro Susceptibility Surveillance Group.哌拉西林-他唑巴坦与11种选定的β-内酰胺类抗生素及环丙沙星对42000多株需氧革兰氏阳性和革兰氏阴性菌体外活性的多中心评估。体外药敏监测组。
Diagn Microbiol Infect Dis. 1994 Jun;19(2):111-20. doi: 10.1016/0732-8893(94)90121-x.
4
Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).优化哌拉西林与他唑巴坦(YTR 830)体外试验的研究。
Diagn Microbiol Infect Dis. 1989 Nov-Dec;12(6):495-510. doi: 10.1016/0732-8893(89)90084-9.
5
Comparative in vitro evaluation of piperacillin/tazobactam in a tertiary care hospital.一家三级护理医院中哌拉西林/他唑巴坦的体外比较评估
J Chemother. 1997 Oct;9(5):336-40. doi: 10.1179/joc.1997.9.5.336.
6
Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.哌拉西林-他唑巴坦与替卡西林-克拉维酸的体外活性比较
Antimicrob Agents Chemother. 1989 Aug;33(8):1268-74. doi: 10.1128/AAC.33.8.1268.
7
Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program.用于医院获得性肺炎经验性治疗的抗菌药物药效学:OPTAMA项目报告
Crit Care Med. 2005 Oct;33(10):2222-7. doi: 10.1097/01.ccm.0000181528.88571.9b.
8
Multicentre survey of the comparative in-vitro activity of piperacillin/tazobactam against bacteria from hospitalized patients in the British Isles.哌拉西林/他唑巴坦对不列颠群岛住院患者分离细菌的体外活性比较的多中心调查。
J Antimicrob Chemother. 1993 Aug;32(2):247-66. doi: 10.1093/jac/32.2.247.
9
In vitro activity of piperacillin/tazobactam versus other broad-spectrum antibiotics against nosocomial gram-negative pathogens isolated from burn patients.哌拉西林/他唑巴坦与其他广谱抗生素对从烧伤患者中分离出的医院革兰氏阴性病原菌的体外活性。
J Chemother. 1998 Jun;10(3):208-14. doi: 10.1179/joc.1998.10.3.208.
10
Argentinean collaborative multicenter study on the in vitro comparative activity of piperacillin-tazobactam against selected bacterial isolates recovered from hospitalized patients.阿根廷关于哌拉西林-他唑巴坦对从住院患者中分离出的特定细菌菌株的体外比较活性的多中心合作研究。
Diagn Microbiol Infect Dis. 2003 Nov;47(3):527-37. doi: 10.1016/s0732-8893(03)00131-7.

引用本文的文献

1
The development of beta-lactam antibiotics in response to the evolution of beta-lactamases.β-内酰胺类抗生素针对β-内酰胺酶的演变而发展。
Pharm Res. 2001 Oct;18(10):1391-9. doi: 10.1023/a:1012272403776.
2
Relative efficacy of tazobactam, sulbactam and clavulanic acid in enhancing the potency of ampicillin against clinical isolates of Enterobacteriaceae.他唑巴坦、舒巴坦和克拉维酸增强氨苄西林对肠杆菌科临床分离株抗菌效力的相对疗效
Eur J Clin Microbiol Infect Dis. 1993 Mar;12(3):200-5. doi: 10.1007/BF01967112.
3
Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection.
在体外感染模型中,哌拉西林单独及与他唑巴坦联合应用对耐哌拉西林和哌拉西林敏感菌的药效学研究。
Antimicrob Agents Chemother. 1994 Oct;38(10):2351-6. doi: 10.1128/AAC.38.10.2351.
4
Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.哌拉西林/他唑巴坦:抗菌活性、药代动力学特性及治疗潜力综述
Drugs. 1994 Mar;47(3):506-35. doi: 10.2165/00003495-199447030-00008.
5
Future directions in antimicrobial chemotherapy.抗菌化疗的未来发展方向。
Pharm Weekbl Sci. 1992 Aug 21;14(4A):229-44. doi: 10.1007/BF01962545.
6
Comparison of fixed concentration and fixed ratio options for testing susceptibility of gram-negative bacilli to piperacillin and piperacillin/tazobactam.
Eur J Clin Microbiol Infect Dis. 1992 Aug;11(8):728-32. doi: 10.1007/BF01989979.